Matches in Wikidata for { <http://www.wikidata.org/entity/Q105089042> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q105089042 description "clinical trial" @default.
- Q105089042 description "ensayo clínico" @default.
- Q105089042 description "ensayu clínicu" @default.
- Q105089042 description "klinisch onderzoek" @default.
- Q105089042 description "клінічне випробування" @default.
- Q105089042 description "临床试验" @default.
- Q105089042 name "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 name "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 type Item @default.
- Q105089042 label "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 label "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 prefLabel "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 prefLabel "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 P1132 Q105089042-CE7F39CB-2CF3-46AD-84EA-5CC01E909A2C @default.
- Q105089042 P1476 Q105089042-53C4E9D9-2ED9-4652-900A-571E785985EA @default.
- Q105089042 P3098 Q105089042-32EB79F3-16FA-487C-A055-4A01B3674C94 @default.
- Q105089042 P31 Q105089042-555DA93A-B50F-41B4-B191-989AF540B1AB @default.
- Q105089042 P580 Q105089042-11280875-C9F7-44A1-8735-34A5A13A5CA9 @default.
- Q105089042 P582 Q105089042-FFDFEDB6-3D15-40C9-9A50-E0607AECA489 @default.
- Q105089042 P6099 Q105089042-8C2F3564-EA77-436A-AFC4-0E946FDB0DDF @default.
- Q105089042 P8005 Q105089042-F6D4FDB2-6D5D-4538-92D6-88A69EDA815C @default.
- Q105089042 P8363 Q105089042-73537158-5130-4DA2-B0A4-BBAF7E1D08C6 @default.
- Q105089042 P859 Q105089042-9FCA4089-A23C-4A72-BD40-067F3B657C07 @default.
- Q105089042 P921 Q105089042-35127FCD-C5CE-401B-8EFD-61D72179D3FA @default.
- Q105089042 P921 Q105089042-5BE2F1EE-7E9A-41D3-BA90-D725DDDBC790 @default.
- Q105089042 P921 Q105089042-E443B7B8-A114-40AA-B841-FD04B9A4F6A7 @default.
- Q105089042 P1132 "+130" @default.
- Q105089042 P1476 "An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study" @default.
- Q105089042 P3098 "NCT04657822" @default.
- Q105089042 P31 Q30612 @default.
- Q105089042 P580 "2021-04-28T00:00:00Z" @default.
- Q105089042 P582 "2028-11-30T00:00:00Z" @default.
- Q105089042 P6099 Q42825046 @default.
- Q105089042 P8005 Q76649614 @default.
- Q105089042 P8363 Q78089383 @default.
- Q105089042 P859 Q507154 @default.
- Q105089042 P921 Q185034 @default.
- Q105089042 P921 Q4162393 @default.
- Q105089042 P921 Q7916864 @default.